See the DrugPatentWatch profile for Keytruda
Keytruda, an immunotherapy drug, has annual costs that can vary significantly depending on the dosage, treatment duration, and patient's insurance coverage [1]. While exact figures are not publicly disclosed for all scenarios, published price lists can provide an indication.
What is the list price for Keytruda?
The list price for Keytruda can be substantial. For example, a 100 mg vial has been priced around $8,300. This means a typical course of treatment, which might require multiple vials per infusion, can amount to tens of thousands of dollars per year [2].
How much does Keytruda treatment cost per year?
Estimates for the annual cost of Keytruda treatment often range from $100,000 to over $200,000 per patient [3][4]. This broad range accounts for the different indications for which Keytruda is prescribed, each potentially requiring different dosing schedules and treatment lengths. For instance, some patients might receive infusions every three weeks, while others might have a different schedule based on their specific cancer type and stage [1].
What financial assistance is available for Keytruda patients?
For patients facing the high cost of Keytruda, pharmaceutical companies often provide patient assistance programs. These programs aim to lower out-of-pocket expenses for eligible individuals who meet certain financial criteria [5]. Additionally, insurance plans play a crucial role, with coverage levels heavily influencing a patient's final cost [4].
How does Keytruda's cost compare to other cancer treatments?
Keytruda is considered a high-cost specialty drug, a category that includes many advanced cancer therapies. The cost of immunotherapy drugs like Keytruda is often higher than traditional chemotherapy, reflecting the complex biological mechanisms and extensive research and development involved [6]. When comparing to other targeted therapies or immunotherapies, Keytruda's price is generally in line with similar innovative treatments [3].
When does Keytruda's patent exclusivity expire?
Keytruda is protected by several patents, which are critical for maintaining its market exclusivity and pricing power. The expiration dates for these patents vary, with some key patents expected to expire in the mid-to-late 2020s and early 2030s [7]. The exact timing of patent expiry is a subject of ongoing legal challenges and can be influenced by patent litigation outcomes [8].
Can biosimilar versions of Keytruda become available?
Following patent expiry, biosimilar versions of Keytruda could potentially enter the market. Biosimilars are highly similar to the original biologic drug and are expected to offer a lower-cost alternative [7]. However, the development and approval process for biosimilars is lengthy and complex, and their market entry is dependent on patent challenges and regulatory pathways [8].
What are the risks of high Keytruda costs for patients and the healthcare system?
The high cost of Keytruda presents significant challenges. For patients, it can lead to financial strain, reduced access to treatment, or reliance on assistance programs [4]. For the healthcare system, such high drug expenditures contribute to rising overall healthcare costs, potentially impacting insurance premiums and government healthcare budgets [3][6].
Who manufactures Keytruda?
Keytruda (pembrolizumab) is manufactured by Merck & Co., Inc. [1].
Sources:
[1] https://www.keytruda.com/
[2] https://www.goodrx.com/keytruda
[3] https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab
[4] https://www.cancercare.org/publications/184-understandingthecostofcancer_treatment
[5] https://www.merck.com/company/patients-access/patient-support-programs/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581746/
[7] https://www.reuters.com/business/healthcare/mercks-keytruda-faces-patent-challenges-setting-stage-biosimilar-competition-2023-05-23/
[8] https://www. FiercePharma.com/Pharma/Mercks-Keytruda-patent-challenges-heat-up-as-biosimilar-battle-looms